Name: Urotensin II Peptide - Rat [Pyr110] for Research Applications
Availability: InStock
Rating: 4.5 (89 reviews)

Urotensin II, rat; [Pyr110]-Prepro-Urotensin II (110-123), rat

Urotensin II, rat; [Pyr¹¹⁰]-Prepro-Urotensin II (110-123), rat is a synthetic 14-amino acid cyclic peptide corresponding to the mature, active form of rat Urotensin II, featuring an N-terminal pyroglutamate modification, intramolecular disulfide bond, and C-terminal amidation. Supplied as a lyophilized powder with ≥95% HPLC purity and low endotoxin levels, this research-grade peptide represents the species-specific rat ortholog of Urotensin II, providing a potent and selective tool for studying UT receptor signaling in rat models of cardiovascular disease, fibrosis, and inflammation. It offers researchers a reliable reagent for investigating the physiological and pathophysiological roles of the urotensin system in rodent-based preclinical studies.

Send Email

Download

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	Urotensin II, rat; [Pyr110]-Prepro-Urotensin II (110-123), rat
CAS NO.	/
Appearance	White to off-white lyophilized powder
Molecular Formula	C77H102N18O20S2
Molecular Weight	1663.9 g/mol
Purity (RP-HPLC)	≥ 95.0%
Solubility	Soluble in water, phosphate‑buffered saline (PBS), or dilute acetic acid (e.g., 0.1% v/v). It is recommended to first dissolve in a small volume of 0.1% acetic acid or sterile water to prepare a 0.1–1.0 mg/mL stock solution.
Endotoxin	< 1.0 EU/mg
Biological Activity	This peptide corresponds to the cyclic, mature form of rat Urotensin II, derived from its precursor. It acts as a potent agonist for the urotensin II receptor (UT, GPR14), exhibiting strong vasoconstrictor activity, and is involved in cardiovascular regulation, fibrosis, and inflammation. Bioactivity is typically validated by vasoconstriction assays in isolated rat vessels or calcium mobilization in UT‑expressing cells.
Storage Conditions	Lyophilized powder: Store desiccated at –20 °C or below, protected from light, for long‑term stability. Reconstituted solution: Aliquot and store at ≤ –20 °C; avoid repeated freeze‑thaw cycles. For extended stability, store at –80 °C.
Stock Location	Stock in USA
MOQ	1g

1.MECHANISM OF ACTION

This peptide exerts its biological effects by binding with high affinity to the urotensin II receptor UT (GPR14), primarily coupling to Gq/11 proteins to activate phospholipase C and increase intracellular calcium mobilization. This signaling cascade induces potent vasoconstriction in vascular smooth muscle cells, modulates cardiac contractility, and promotes pro-fibrotic and inflammatory responses in various tissues. The cyclic structure stabilized by the disulfide bond and the N-terminal pyroglutamate modification are critical for receptor recognition and peptide stability, enabling sustained activation of UT-mediated pathways in experimental systems.

2.PRODUCT INDICATIONS

This product is indicated for research applications focused on rat-specific urotensin II signaling in cardiovascular and fibrotic diseases. It is utilized in in vitroassays with UT-expressing cells to study calcium flux, vasoconstriction, and receptor activation kinetics. In in vivostudies, it is administered to rat models to investigate Urotensin II-mediated effects on blood pressure regulation, vascular remodeling, cardiac hypertrophy, and organ fibrosis. The peptide also serves as a reference standard for receptor binding studies, autoradiography, and functional assays to explore the role of the urotensin system in hypertension, heart failure, pulmonary hypertension, and renal fibrosis.

3.CLINICAL EFFICACY OF PRODUCT

Urotensin II, rat; [Pyr¹¹⁰]-Prepro-Urotensin II (110-123), rat has no clinical efficacy or safety profile, as it is strictly a research reagent for preclinical investigations in rodent models. The peptide has not undergone clinical trials, regulatory evaluation, or safety assessment for diagnostic or therapeutic use in humans. While preclinical studies in rats demonstrate its potent vasoconstrictor, pro-fibrotic, and inflammatory effects, these findings remain exploratory and have not been translated into validated clinical interventions. Any potential therapeutic applications targeting the urotensin system would require species-appropriate analogs or modulators with comprehensive pharmacokinetic and safety evaluations.

4.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.